Article Text

Download PDFPDF
Isosorbide dinitrate plus hydralazine was effective for advanced heart failure in black patients

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

 Q In black patients with New York Heart Association (NYHA) class III or IV heart failure (HF) with dilated ventricles, is a fixed dose of isosorbide dinitrate plus hydralazine (ID+H) better than placebo?

Clinical impact ratings GP/FP/Primary care ★★★★★★☆ IM/Ambulatory care ★★★★★☆☆ Internal medicine ★★★★★☆☆ Cardiology ★★★★★★☆


Embedded ImageDesign:

randomised placebo controlled trial (African-American Heart Failure Trial [A-HeFT]).

Embedded ImageAllocation:


Embedded ImageBlinding:

blinded (clinicians, patients, data collectors, outcome assessors, monitoring committee, and statisticians).*

Embedded ImageFollow up period:

18 months.

Embedded ImageSetting:

161 centres in the US.

Embedded ImagePatients:

1050 adults (mean age 57 y, 60% men) self identified as black who had NYHA class III or IV HF for ⩾3 months, had left ventricular dysfunction in the preceding 6 months, and were receiving standard HF therapy. Exclusion criteria included acute MI, stroke, cardiac surgery, or …

View Full Text


  • * See glossary.

  • For correspondence: Dr A Taylor, University of Minnesota Medical School, Minneapolis, MN, USA.

  • Source of funding: NitroMed.

Linked Articles

  • Glossary
    BMJ Publishing Group Ltd